Oscar Mancera-Páez, MD, is a neurologist, neuroscientist, and physician-innovator whose work bridges epigenetics, neurotechnology, and precision neurology. Trained across leading centers including, Houston Methodist, UTHealth Houston, the Texas Institute of Restorative Neurotechnologies, and the National University of Colombia, he integrates neurogenetics, metabolomics, MEG, HD-EEG, and stereo-EEG to decode the molecular and network mechanisms driving epilepsy, Alzheimer’s disease, and neuroimmune disorders.
His research is internationally recognized for revealing metabolic–epigenetic pathways in Alzheimer’s disease, including APOE methylation, homocysteine biology, and vitamin-dependent risk modulation. In epilepsy, he helped redefine the field through pioneering work on ictal central apnea (ICA), mapping the amygdala–temporal networks that govern seizure-related respiratory arrest and informing modern SUDEP-risk frameworks.
Now he leads one of Latin America’s most advanced precision-neurology programs, integrating biomarkers, multimodal imaging, electrophysiology, and cognitive analytics to transform early detection of cognitive decline. His career reflects a commitment to data-driven, mechanistic, and globally relevant neuroscience, advancing innovative solutions for complex brain disorders at the intersection of biology, technology, and clinical care.
Oscar Mancera-Páez, MD, is a neurologist, neuroscientist, and physician-innovator whose work bridges epigenetics, neurotechnology, and precision neurology. Trained across leading centers including, Houston Methodist, UTHealth Houston, the Texas Institute of Restorative Neurotechnologies, and the National University of Colombia, he integrates neurogenetics, metabolomics, MEG, HD-EEG, and stereo-EEG to decode the molecular and network mechanisms driving epilepsy, Alzheimer’s disease, and neuroimmune disorders.
His research is internationally recognized for revealing metabolic–epigenetic pathways in Alzheimer’s disease, including APOE methylation, homocysteine biology, and vitamin-dependent risk modulation. In epilepsy, he helped redefine the field through pioneering work on ictal central apnea (ICA), mapping the amygdala–temporal networks that govern seizure-related respiratory arrest and informing modern SUDEP-risk frameworks.
Now he leads one of Latin America’s most advanced precision-neurology programs, integrating biomarkers, multimodal imaging, electrophysiology, and cognitive analytics to transform early detection of cognitive decline. His career reflects a commitment to data-driven, mechanistic, and globally relevant neuroscience, advancing innovative solutions for complex brain disorders at the intersection of biology, technology, and clinical care.